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Studies of Alzheimer’s disease risk-weighted polygenic risk scores (PRSs) for cognitive
performance have reported inconsistent associations. This inconsistency is particularly
evident when PRSs are assessed independent of APOE genotype. As such, the
development and assessment of phenotype-specific weightings to derive PRSs for
cognitive decline in preclinical AD is warranted. To this end a episodic memory-weighted
PRS (emPRS) was derived and assessed against decline in cognitive performance
in 226 healthy cognitively normal older adults with high brain Aβ-amyloid burden
participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. The
effect size for decline in a verbal episodic memory was determined individually for 27
genetic variants in a reference sample (n = 151). These were then summed to generate
a emPRS either including APOE (emPRSc¯APOE) or excluding APOE (emPRSs¯APOE).
Resultant emPRS were then evaluated, in a test sample (n = 75), against decline in
global cognition, verbal episodic memory and a pre-Alzheimer’s cognitive composite
(AIBL-PACC) over 7.5 years. The mean (SD) age of the 226 participants was 72.2
(6.6) years and 116 (51.3%) were female. Reference and test samples did not differ
significantly demographically. Whilst no association of emPRSs were observed with
baseline cognition, the emPRSc¯APOE was associated with longitudinal global cognition
(−0.237, P = 0.0002), verbal episodic memory (−0.259, P = 0.00003) and the AIBL-
PACC (−0.381, P = 0.02). The emPRSs¯APOE was also associated with global cognition
(−0.169, P = 0.021) and verbal episodic memory (−0.208, P = 0.004). Stratification by
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APOE ε4 revealed that the association between the emPRS and verbal episodic memory
was limited to carriage of no ε4 or one ε4 allele. This was also observed for global
cognition. The emPRS and rates of decline in AIBL-PACC were associated in those
carrying one ε4 allele. Overall, the described novel emPRS has utility for the prediction
of decline in cognition in preclinical AD. This study provides evidence to support the
further use and evaluation of phenotype weightings in PRS development.
Keywords: polygenic risk score, Alzheimer’s disease, Aβ-amyloid, cognitive decline, episodic memory
INTRODUCTION
An improved understanding of the extended preclinical phase
of Alzheimer’s disease (AD), has seen an increased focus on
early disease intervention (Sperling et al., 2014). As a result,
importance has been placed on investigating potential factors
that could underpin the significant variability in cognitive
decline between individuals in this early stage of the disease.
Accumulation of Aβ-amyloid (Aβ) occurs up to 20 years prior to
symptom onset (Villemagne et al., 2013). In addition, abnormally
high neocortical Aβ in cognitively normal (CN) older adults
is associated with an increased risk for cognitive decline and
development of AD (Villemagne et al., 2011). Despite this,
levels of Aβ alone do not track well with progressive cognitive
decline and there is strong convergent evidence that variable
rates of decline in the preclinical stages of AD may be influenced
by genetic factors (Lim et al., 2015a,b; Porter et al., 2018a,c).
Identification of genetic factors that contribute to accelerated
rates of cognitive decline in at risk individuals will be of
significant importance, through an increased understanding of
potential mechanisms of preclinical decline and the identification
of individuals most suitable for intervention trials.
One method frequently investigated for use as a predictor
of cognitive performance and decline employs polygenic risk
scores (PRSs). These are typically focused on AD risk associated
genes identified through genome wide association studies
(GWAS). Once identified, these genetic variants are weighted
by their respective effect sizes and summed. The resulting
scores have then been used for the analysis of associations with
clinical and pathological variables including: measures of clinical
classification (Biffi et al., 2010; Rodriguez-Rodriguez et al., 2013;
Chauhan et al., 2015; Escott-Price et al., 2015, 2017; Sleegers
et al., 2015; Chouraki et al., 2016; Mormino et al., 2016; Desikan
et al., 2017; Lacour et al., 2017), disease progression, and fluid
(Sabuncu et al., 2012; Martiskainen et al., 2015; Sleegers et al.,
2015; Louwersheimer et al., 2016) and imaging (Biffi et al., 2010;
Sabuncu et al., 2012; Chauhan et al., 2015; Habes et al., 2016;
Harrison et al., 2016; Lupton et al., 2016; Mormino et al., 2016;
Foley et al., 2017) biomarkers. However, inconsistent findings
have been reported when investigating associations of PRSs
with cognition. Almost equally, studies have observed significant
associations with cognitive performance (Sabuncu et al., 2012;
Carrasquillo et al., 2015; Andrews et al., 2016; Louwersheimer
et al., 2016; Marden et al., 2016; Mormino et al., 2016) or an
absence of association (Gui et al., 2014; Harrison et al., 2016;
Bressler et al., 2017; Darst et al., 2017).
We have previously reported that while an AD risk weighted
PRS was associated with cognitive decline (Porter et al.,
2018b), the association was only observed in carriers of the
apolipoprotein E (APOE) ε4 allele. This is consistent with other
studies which have reported no association with cognition when
APOE was removed from the calculation of a PRS (Carrasquillo
et al., 2015; Andrews et al., 2016). In addition to being the
strongest known genetic risk factor for the development of AD,
the ε4 allele of APOE has previously been associated with cross-
sectional and longitudinal cognitive performance (Lim et al.,
2015b). Of particular interest, carriage of APOE ε4 in CN older
adults at risk for AD (determined by Aβ brain imaging) is
associated with accelerated decline in multiple cognitive domains
(Lim et al., 2015b).
In addition to APOE, a number of genetic variants with no
or limited association with AD risk have been independently
associated with cognitive performance in diseased, at risk and
healthy populations. The genes containing these variants have
roles in promotion of neuronal survival (BDNF; Brain Derived
Neurotropic Factor; (Lim et al., 2015a), synaptic plasticity
(KIBRA; Kidney and Brain expressed protein; (Tracy et al., 2016;
Porter et al., 2018a), regulation of dopamine availability (COMT;
Catechol-O-methyltranferase; Sheldrick et al., 2008), longevity
(KL; Klotho; Arking et al., 2002), inflammation (CSMD1; CUB
and Sushi Multiple Domain 1; Kraus et al., 2006) and amyloid
precursor protein (APP) processing (SPON1; Spondin 1; Ho and
Sudhof, 2004). In addition to the independent association of
these genes with cognitive performance, we have also recently
reported on the utility of combining these cognition-associated
genetic variants for assessing longitudinal cognition (Porter et al.,
2018c). As identified above there is also a significant body of
literature combining GWAS derived AD risk associated genetic
variants, typically within a core set of 21 genes, into PRSs that
have previously been associated with the clinical classification
of AD and disease phenotypes, albeit with inconsistency of
association with cognition. However, there are few studies that
have investigated the combination of AD risk and cognition
associated variants. This is likely due the possible dilution of
the effects of the cognition associated genetic variants when
their weak AD risk weightings are applied (Andrews et al.,
2016).
Reasons for the inconsistency of studies investigating PRSs
may be twofold. First, cognition has significant inter-individual
variability, particularly in the elderly, which works to increase
the difficulty of predicting rates of cognitive decline. Second,
late disease stage methods of weighting, such as AD risk,
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may not be suitable for predicting cognitive decline at early
preclinical stages. As such, a cognitive phenotype, such as
verbal episodic memory, may be more appropriate as it is
typically observed to precede decline in executive function by
4–8 years and between 7 and 10 years before other domains
(Elias et al., 2000; Grober et al., 2008; Derby et al., 2013).
The hypothesis of this study was therefore: through combining
individually weighted AD risk and cognitive decline associated
genetic variants, by endophenotype effect-sizes, a PRS can
be derived with utility for prediction of preclinical rates of
cognitive decline. Further, by focusing on CN older adults
with high levels of neocortical Aβ, population heterogeneity,
and so cognitive performance variability, is reduced. To test
this hypothesis, the study undertook a targeted approach
to the development and assessment of utility of a novel
episodic memory-weighted PRS (emPRS), by weighting each
genetic variant by its effect on decline in verbal episodic
memory, in CN older adults with high neocortical Aβ
burden.
MATERIALS AND METHODS
Study Participants
Data is reported on 232 CN older adults enrolled in the Australian
Imaging Biomarkers and Lifestyle (AIBL) Study of Ageing. The
AIBL Study is a prospective longitudinal study of aging, the study
design, enrolment process, neuropsychological assessments, and
diagnostic criteria have been previously described (Ellis et al.,
2009). Briefly, a participant was classified by a clinical review
panel (Ellis et al., 2009), blinded to Aβ-amyloid status, as CN
if they did not meet the clinical criteria for diagnosis of mild
cognitive impairment (MCI) (Winblad et al., 2004) or dementia
(McKhann et al., 1984). Ethics approval was granted for the
study by each member institution, including Austin Health,
Edith Cowan University, Hollywood Private Hospital, and St
Vincent’s Health. All participants provided informed written
consent.
Cognitive Measures
The AIBL neuropsychological test battery consists of the
Mini-Mental State Examination (MMSE), Clock Drawing Test,
California Verbal Learning Test-Second edition (CVLT-II),
Logical Memory I and II (LMI; LMII; Story A only), D-KEFS
verbal fluency, a 30-item version of the Boston Naming Test
(BNT), Wechsler Test of Adult Reading (WTAR), Digit Span
and Digit Symbol-Coding subtests of the Wechsler Adult
Intelligence Scale-Third edition (WAIS-III), the Stroop task
(Victoria version), and the Rey Complex Figure Test (RCFT)
(Ellis et al., 2009). Test results were used in combination to
calculate cognitive composite scores, as previously described
(Donohue et al., 2014; Burnham et al., 2015, 2016). Specifically,
in this study these composite scores included a measure
of global cognition (CDR sum of boxes (CDRSB), MMSE,
LMII, CVLT-II recognition false positives (CVLT-IIFP) and
Clock) and verbal episodic memory (CDRSB, LMII, CVLT-IIFP)
(Burnham et al., 2015), in addition to a composite of tests
shown to be sensitive to decline in preclinical AD [AIBL-pre-
Alzheimer’s cognitive composite (PACC); CVLT-IILDFR, LMII,
MMSE, WAIS- IIIDS−C] (Donohue et al., 2014; Burnham
et al., 2016). The calculation of the aforementioned composites
involved corrections for age, sex, years of education, premorbid
IQ [WTAR-estimated WAIS-III Full Scale Intelligence Quotient
(FSIQ)] and depressive symptoms [Geriatric Depression Scale
(GDS)] (Donohue et al., 2014). The AIBL-PACC did not include
an age correction, however, this was included as a covariate
in subsequent analyses. 7.5 years of cognitive assessment data
was utilized with collections occurring at 0, 18, 36, 54, 72, and
90 months.
Amyloid Imaging
All participants were imaged for neocortical Aβ by positron
emission tomography (PET) using one of the following
radiolabelled tracers; 11C-Pittsburgh Compound B (PiB), 18F-
florbetapir or 18F-flutemetamol, as previously described (Rowe
et al., 2010; Vandenberghe et al., 2010; Clark et al., 2011).
CapAIBL R©, a web-based, freely available software, was used
to generate PET standardized uptake value (SUV) ratios
(SUVR) for all tracers without the requirement for magnetic
resonance imaging (Bourgeat et al., 2015). Target-region to
reference-region SUVRs were calculated by the summation
and normalization of SUVs to brain regions specific to each
tracer [PiB (cerebellar cortex), florbetapir (whole cerebellum),
flutemetamol (pons)]. All participants included in this study
were classified as having a high Aβ (Aβhigh) burden at any
time point, as determined by tracer specific thresholds of
≥1.4, ≥1.05 and ≥0.55 for PiB, florbetapir and flutemetamol
respectively.
SNP Selection and Genotyping
A thorough literature review was conducted in PubMed and
27 single nucleotide polymorphisms (SNPs) were selected
based on a priori evidence of associations with either AD
risk or cognitive performance (or both; Table 1). Of these,
21 variants had previously been associated with the clinical
classification of AD and disease phenotypes. The remaining
six variants had previously been associated with cross-sectional
and longitudinal cognitive phenotypes in cognitively normal
and/or demented individuals. QIAamp DNA Blood Maxi Kits
(Qiagen, Hilden, Germany) were used for the extraction of
DNA from 5 mL of whole blood. TaqMan R© assays with the
TaqMan R© GTXpressTM Master Mix (Life Technologies) were
used to genotype APOE (rs7412, assay ID: C____904973_10;
rs429358, assay ID: C___3084793_20; Life Technologies,
Carlsbad, CA, United States) on a QuantStudio 12K FlexTM
Real-Time-PCR system (Applied Biosystems, Foster City, CA,
United States). QIAamp and TaqMan R© kits detailed above
were used following manufacturer’s instructions. Genotype
information for the additional SNPs included in the PRS
were extracted from a genome-wide SNP array conducted
on the Illumina OmniExpressHumanExome+ BeadChip
with subsequent imputation using impute2 ver2.3, with the
1000 genome reference panel (2015 release). Complete SNP
information was available for the 232 individuals included in
Frontiers in Aging Neuroscience | www.frontiersin.org 3 December 2018 | Volume 10 | Article 423
fnagi-10-00423 December 18, 2018 Time: 16:29 # 4
Porter et al. emPRS in Preclinical AD
TABLE 1 | Single nucleotide polymorphisms (SNP) information.
Gene SNP Chromosome Position Minor allele Risk genotype AIBL Effect Size d (95% CI)
APOE rs7412 rs429358 19 44908822 44908684 ε4 ε4+ 0.472 (0.14 – 0.80)
CR1 rs3818361 1 207611623 A G/G 0.109 (−0.24 – 0.46)
BIN1 rs744373 2 127137039 G A/A 0.003 (−0.32 – 0.33)
INPP5D rs35349669 2 233159830 T T+ 0.153 (−0.20 – 0.50)
KIBRA rs17070145 5 168418786 C C/C 0.097 (−0.22 – 0.42)
MEF2C rs190982 5 88927603 G A/A 0.278 (−0.07 – 0.62)
HLA cluster rs9271192 6 32610753 C C+ 0.256 (−0.07 – 0.58)
CD2AP rs9349407 6 47485642 C C+ 0.114 (−0.21 – 0.43)
NME8 rs2718058 7 37801932 G G+ 0.041 (−0.28 – 0.36)
ZCWPW1 rs1476679 7 100406823 C T/T 0.149 (−0.17 – 0.47)
EPHA1 rs11767557 7 143412046 C T/T 0.061 (−0.27 – 0.39)
CSMD1 rs2740931 8 4022021 A A/A 0.201 (−0.16 – 0.56)
CLU rs11136000 8 27607002 T T+ 0.078 (−0.25 – 0.40)
PTK2B rs28834970 8 27337604 C C+ 0.030 (−0.30 – 0.36)
SPON1 rs11023139 11 14202800 A A+ 0.045 (−0.44 – 0.53)
BDNF rs6265 11 27658369 Met Met+ 0.143 (−0.20 – 0.49)
CELF1 rs10838725 11 47536319 C C+ 0.103 (−0.22 – 0.42)
MS4A6A rs610932 11 60171834 T T+ 0.167 (−0.18 – 0.52)
PICALM rs3851179 11 86157598 T C/C 0.098 (−0.23 – 0.42)
SORL1 rs11218343 11 121564878 C T/T 0.214 (−0.68 – 1.10)
KL rs9536314 13 33054001 VS VS+ 0.160 (−0.20 – 0.52)
FERMT2 rs17125944 14 52933911 C C+ 0.277 (−0.15 – 0.71)
SLC24A4 rs10498633 14 92460608 T T+ 0.110 (−0.21 – 0.43)
ABCA7 rs3764650 19 1046521 G G+ 0.062 (−0.34 – 0.47)
CD33 rs3865444 19 51224706 A A+ 0.082 (−0.24 – 0.40)
CASS4 rs7274581 20 56443204 C T/T 0.080 (−0.36 – 0.52)
COMT rs4680 22 19963748 Met Met+ 0.098 (−0.26 – 0.45)
Location and risk information on the 27 genetic variants included in the calculation of the PRS. Minor alleles for SNPs based on published 1000 Genomes Phase 3
European allele frequencies(Genomes Project et al., 2015). Effect sizes [Cohen’s d and 95% Confidence Interval (CI)] are presented with their accompanying risk genotype
as per calculation in AIBL. SNP, single nucleotide polymorphism; AIBL, Australian Imaging, Biomarkers and Lifestyle Study of Aging.
the study. However, 6 samples were excluded from further
analysis due to homozygosity of KL-VS variant, which has
been reported to confer phenotypic risk not in a gene dosage
dependent fashion (Arking et al., 2003). Analysis of all SNPs
was performed using the dominant model of minor allele
(Table 1).
Statistical Analysis
Rstudio (RStudio Team 2015) Version 0.98.1103 for Macintosh
was used for all statistical analyses (RStudio Team, 2015).
226 Aβhigh CN older adults were randomly split using the
“sample” function of the R “base” package, creating the reference
(n = 151) and test (n = 75) samples sets. Means/counts and
standard deviations/percentages for demographic variables for
the reference and test groups were then determined. To ensure
the reference and test samples were not significantly different
in demographic measures analysis of covariance (ANOVA; age,
premorbid IQ, depressive symptoms) and chi-squared tests
(gender, years of education, APOE ε4+ve) were performed.
Calculation of an individual’s emPRS was by the summation
of each SNP’s effect size for the risk allele, if the risk allele is
present. This can be represented as emPRS =
∑
RAn(dn); where
n is each individual SNP, RA is the presence (1) or absence (0)
of risk allele of n, and d is the calculated effect size for the risk
allele of n. To calculate d, changes in verbal episodic memory
performance for individual participants in the reference sample
(n = 151) were calculated for each SNP using random intercepts
linear mixed effects (LME) models, as implemented in the “nlme”
package in R, in a dominant model for the minor allele. The
resultant mean and standard deviation of the β-coefficient, for the
verbal episodic memory slopes, were used to determine the effect
sizes for all SNPs (Table 1) using the “effsize” package in R. The
resultant effect sizes were then used to assign the risk genotype
for each variant. Individual sample emPRSs were then calculated
by summing the effect sizes if the assigned risk genotypes were
present. We have previously reported that the utility of PRSs for
prediction of cognitive decline are dependent on the inclusion of
APOE genotype in their construction (Porter et al., 2018b). As
such we wished to determine whether the utility of the emPRS
defined in this study was likewise dependent on the inclusion
of APOE. To this end each individual in the test sample had
two emPRSs calculated. The first included APOE (emPRSc¯APOE)
whilst the second excluded APOE (emPRSs¯APOE).
Random intercepts LME models were used to assess
associations between both emPRSc¯APOE and emPRSs¯APOE and
cognitive performance in the test sample (n = 75). Modeling was
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again performed using the “nlme” R package. For all analyses,
the cognitive composite scores were included as dependent
variables, emPRS × Time interactions as fixed factors, and
participant baseline scores as random factors. Additionally,
those analyses investigating associations with AIBL-PACC
performance included age as a covariate. Further, the test sample
was then stratified based on the number of APOE ε4 alleles
carried, and the model described above was used to determine
associations of the emPRSs¯APOE in each group. All models were
graphically represented as baseline or change in composite score
given emPRS, with error shading signifying emPRS dependent
standard error.
RESULTS
SNP Information, PRS Calculation and
Demographics
A total of 27 SNPs were identified and selected for inclusion into
the current emPRSs. Effect sizes were calculated for the selected
SNPs, based on their discriminatory effect on decline in verbal
episodic memory in the reference cohort. These are presented
with corresponding 95% confidence intervals in Table 1. The
effect sizes ranged from APOE, with the largest effect size
(d = 0.472), to BIN1 with the smallest (d = 0.003). These
effect sizes were then used for weighting of each SNP in the
calculated emPRS in the test cohort. No significant differences
were identified between the reference (n = 151) and test (n = 75)
samples for the baseline demographic measures (Table 2).
TABLE 2 | Demographic information.
Overall Reference Test P
(n = 226) (n = 151) (n = 75)
Age, mean (SD),
years
72.24 (6.57) 72.02 (6.48) 72.69 (6.78) 0.482
Female, No. (%) 116 (51.33) 77 (50.99) 39 (52.00) 0.999
Years of
Education, No.
(%)
0–8 years 20 (8.93) 10 (6.67) 10 (13.51) 0.221
9–12 years 84 (37.50) 55 (36.67) 29 (39.19)
13–15 years 50 (22.32) 33 (22.00) 17 (22.97)
15+ years 70 (31.25) 52 (34.67) 18 (24.32)
Premorbid IQ
(FSIQ), mean (SD)
108.06 (7.46) 108.01 (7.68) 108.18 (7.05) 0.872
Depressive
Symptoms (GDS),
mean (SD)
1.01 (1.23) 1.08 (1.29) 0.87 (1.11) 0.318
APOE ε4 carriage,
No. (%)
95 (42.04) 61 (40.40) 34 (45.33) 0.572
Baseline demographic and clinical characteristics for all cognitively normal older
adults with high Aβ (Aβhigh) in the AIBL study, and stratified by the reference
(n = 152) and test (n = 75) cohorts utilized in the current study. Values
represented as mean/count (standard deviation/percentage). Significance of
statistical difference between reference and test cohorts represented by p-values.
GDS, Geriatric Depression Scale; FSIQ, Wechsler Adult Intelligence Scale-Third
Edition (WAIS-III) Full Scale Intelligence Quotient.
emPRSc¯APOE and emPRSs¯APOE Are
Associated With Longitudinal Cognition
in Aβhigh CN Older Adults
No significant associations were observed between emPRSc¯APOE
or emPRSs¯APOE and performance at baseline for global cognition
(emPRSc¯APOE: −0.172, p = 0.655; emPRSs¯APOE: 0.098, p = 0.836),
verbal episodic memory (emPRSc¯APOE: −0.144, p = 0.706;
emPRSs¯APOE: 0.125, p = 0.791) or the AIBL-PACC (emPRSc¯APOE:
0.143, p = 0.892; emPRSs¯APOE: 0.786, p = 0.541) (Figures 1, 2).
The emPRSc¯APOE was significantly associated with longitudinal
cognitive performance as measured by global cognition (−0.237,
p = 0.0002), verbal episodic memory (−0.259, p = 0.00003) and
the AIBL-PACC (−0.381, p = 0.020) (Figure 1). Specifically, in
the test cohort, as the emPRSs¯APOE increased the rate of decline in
cognitive outcomes worsened.
To assess whether these associations were dependent upon the
inclusion of APOE in the calculation, the emPRS was calculated
excluding APOE. This derived emPRS, emPRSs¯APOE, was likewise
observed to be significantly associated with longitudinal global
cognition (−0.169, p = 0.021) and verbal episodic memory
(−0.208, p = 0.004) performance, albeit to a reduced extent
(Figure 2). However, it was no longer associated with decline
on the AIBL-PACC (−0.152, p = 0.420). As was the case
when investigating emPRSc¯APOE, an increase in emPRSs¯APOE was
significantly associated with a concomitant increased rate of
cognitive decline.
emPRSs¯APOE Is Associated With
Longitudinal Cognition in Aβhigh CN
Older Adults, When Stratified by APOE ε4
Carriage
After stratification of the test sample into groups based on
the carriage of the APOE ε4 allele, association between the
emPRSs¯APOE and cognition was evaluated separately. Significant
associations between the emPRSs¯APOE and longitudinal measures
of verbal episodic memory and global cognition were observed
irrespective of APOE ε4 status (Table 3). However, the
emPRSs¯APOE association with decline in the AIBL-PACC was
limited to APOE ε4 carriers. Finally, no associations were
observed in any groups when investigating baseline levels of
cognition.
DISCUSSION
This study describes a emPRS developed by weighting AD
risk and cognition associated genetic variants by their effect
on decline in verbal episodic memory in a cohort defined
in terms of pre-clinical AD by reference to neocortical Aβ
PET imaging. The emPRSs were calculated in the test sample
by the summation of gene variant effect sizes calculated with
respect to decline in episodic memory in the reference sample.
In the test sample no associations were observed between the
emPRSs and baseline levels of cognition, however, associations
with longitudinal performance were statistically significant. The
emPRSc¯APOE was significantly associated with decline in global
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FIGURE 1 | Association between emPRSc¯APOE and baseline and longitudinal change in cognition in Aβhigh CN older adults. Association between emPRSc¯APOE and
baseline (A,C,E) and longitudinal change (B,D,F) in composite measures of cognition including a statistically driven global composite (A,B), verbal episodic memory
composite (C,D), and Pre-Alzheimer’s Cognitive Composite (AIBL-PACC; E,F) in cognitively normal (CN) older adults with high Aβ (Aβhigh; n = 75). AIBL-PACC
controlled for age. Shaded regions represent emPRS dependent standard error. emPRSAPOE, cognition polygenic risk score with APOE genotype.
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FIGURE 2 | Association between emPRSs¯APOE and baseline and longitudinal change in cognition in Aβhigh CN older adults. Association between emPRSs¯APOE and
baseline (A,C,E) and longitudinal change (B,D,F) in composite measures of cognition including a statistically driven global composite (A,B), verbal episodic memory
composite (C,D), and Pre-Alzheimer’s Cognitive Composite (AIBL-PACC; E,F) in cognitively normal (CN) older adults with high Aβ (Aβhigh; n = 75). AIBL-PACC
controlled for age. Shaded regions represent emPRS dependent standard error. emPRSs¯APOE, cognition weighted polygenic risk score without APOE genotype.
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TABLE 3 | Association between emPRSs¯APOE and baseline and longitudinal
change in cognition in Aβhigh CN older adults.
α P β P
APOEε4 non-carrier (n = 41)
Global 0.210 0.619 −0.145 0.044
Verbal Episodic Memory 0.242 0.575 −0.185 0.011
AIBL-PACC 0.531 0.708 0.086 0.645
APOEε4 carrier (n = 34)
Global 0.032 0.972 −0.329 0.028
Verbal Episodic Memory 0.047 0.958 −0.363 0.013
AIBL-PACC 1.477 0.522 −0.821 0.034
Mean slopes for models assessing the association between emPRS and baseline
(α) and longitudinal (β) change in cognitive composite measures in all cognitively
normal (CN) older adults with high Aβ (Aβhigh; n = 75), and by carriage of the
APOEε4 allele. AIBL-PACC controlled for age. emPRSs¯APOE, cognition weighted
polygenic risk score without APOE genotype.
cognition, verbal episodic memory and the AIBL-PACC (Table 3
and Figure 1). While these associations were strongest when
APOE was included they were not dependent on the inclusion
of APOE ε4, as associations with verbal episodic memory and
global cognition were still observed in the emPRSs¯APOE (Table 3
and Figure 2). Further evidence that the score developed was not
purely dependent on APOE was provided when the participants
were stratified by carriage of the APOEε4 allele. This analysis
showed that the emPRSs¯APOE was significantly associated with
verbal episodic memory and global cognition in both carriers and
non-carriers of the APOEε4 allele.
Previous studies have observed significant associations
between PRSs weighted by a measure of AD risk and cognitive
performance in a number of different domains (Sabuncu
et al., 2012; Carrasquillo et al., 2015; Andrews et al., 2016;
Louwersheimer et al., 2016; Marden et al., 2016; Mormino
et al., 2016). Further, these associations have been reported
in both cognitively normal individuals (Sabuncu et al., 2012;
Andrews et al., 2016; Marden et al., 2016) and those who
had already developed AD (Carrasquillo et al., 2015). Few
studies have investigated the utility of PRSs independent
of APOE genotype or have reported no associations when
APOE was excluded, similar to our previous study (Porter
et al., 2018b). However, two studies have observed significant
associations between clinical and cognitive outcomes and
PRS independent of APOE (Mormino et al., 2016; Desikan
et al., 2017). The major difference in these studies was that
they either involved a phenotype correction within the PRS
calculation (Desikan et al., 2017) or significantly extended
the number of SNPs included in the PRS (Mormino et al.,
2016). Unlike the current study, neither of these prior studies
used a phenotype weighting system for the development of
an APOE independent PRS with a reduced number of genetic
variants. To the best of our knowledge, this is the first PRS
developed through weighting by a cognitive phenotype and
specifically with the aim of predicting decline in a preclinical AD
cohort.
The effect size for APOE observed in the study is similar
to that reported previously in this cohort. One contrast is
that in the previous study it was over a shorter duration
(4.5 years) and used a learning/working memory composite
derived from the online Cogstate Brief Battery (Lim et al.,
2015b). In this study there was no obvious disparity in the
calculated effect sizes between the a priori cognition associated
variants or GWAS-derived AD risk variants. This lack of
disparity supports both our notion of phenotype-specific effect
size driven PRSs, as well as the importance of combining
both cognition and AD risk associated variants. In addition,
after excluding APOE, the variants with the 3 largest effect
sizes in this study were rs190982 [Myocyte-specific enhancer
factor 2C (MEF2C)], rs9271192 (HLA cluster), and rs17125944
[Fermitin family homolog 2 (FERMT2)]. While these variants
were included due to their previous associations with AD risk,
they have been associated (albeit inconsistently) with cognitive
performance and/or decline. In one study, MEF2C was associated
with general cognitive function whilst neither FERMT2 or genes
in the HLA cluster were associated (Davies et al., 2015). In a
further study, analysis of the same variants in the current study
revealed a trend toward association of MEF2C (rs190982) whilst
the HLA cluster (rs9271192), and FERMT2 (rs17125944) were
not significant (Nettiksimmons et al., 2016). However, in the
same study aggregate associations of SNPs within the MEF2C and
HLA loci were associated with cognitive decline (Nettiksimmons
et al., 2016). The protein products of these genes do have
functions in neuronal homeostasis and plasticity that would
indicate they could be associated with maintaining cognitive
functioning. MEF2C is reported to be involved in neurogenesis
(Li et al., 2008), whilst its deletion in the CNS of mice impairs
hippocampal-dependent learning and memory (Barbosa et al.,
2008) and peripheral mRNA expression has been reported to
correlate with memory performance in a Japanese sample (Sao
et al., 2017). The HLA cluster has important roles in the immune
response, and FERMT2 maintains cellular structures including
neuronal cells.
It is acknowledged that the current study has several
limitations. First, AIBL study participants generally have
higher levels of education, which may not be representative
of the broader community (Ellis et al., 2009). Second, the
current study represents a majority Caucasian population and
results may differ based on ethnicity. Finally, small sample
sizes in the resulting reference and test cohorts may have
influenced the results reported. This is evidenced by differences
in the risk alleles of certain SNPs observed in this study,
compared with those previously reported. In addition to these
limitations, several strengths of the AIBL study may impact
replication studies. Firstly, the calculation of effect sizes for PRS
weighting a combined group measure of verbal episodic memory
performance over 7.5 years was utilized. It is possible that studies
of shorter duration could yield differing results. Second, the use
of a composite measure of verbal episodic memory is a further
strength of the study, the same or comparable neuropsychological
tests are likely to be required to calculate appropriate cognitive
composite scores for validation purposes. For this reason, the
replication of the methods and results reported here in large,
comparably comprehensive studies are warranted to validate the
clinical utility of this emPRS.
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CONCLUSION
The study detailed above describes a emPRS for the prediction
of rates of cognitive decline in cognitively normal older adults
at risk for AD. It shows that the emPRS is able to predict
rates of cognitive decline in domains typically affected in the
preclinical stages of AD. Further, this is the first PRS calculated
with a conservative number of genetic variants to be associated
with longitudinal cognition in the absence of APOE. The
reported emPRS has utility in those individuals carrying no or
one copy of the APOE ε4 allele. The results presented here
provide evidence which support the further evaluation and use
of endophenotype weightings in PRS development rather than
the standard AD risk weightings that demonstrate inconsistent
utility. The methodology and results should be validated in
similarly well-characterized cohorts with comparable phenotypic
and longitudinal data.
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